KPTI Quote, Financials, Valuation and Earnings

Actinium Pharmaceuticals, Inc. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of -5701.11%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 148.17%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 244.83%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Karyopharm Therapeutics, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Karyopharm Therapeutics, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.228, which suggesting that the stock is 77.201% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.367, suggesting its less volatile than the S&P 500 by 136.662%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are larger than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is lower than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.35x versus 502.60x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Axsome Therapeutics, Inc. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of -27.62%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 148.17%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $181.31 which suggests that it could grow by 21.41%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.228, which suggesting that the stock is 77.201% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.416%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.35x versus 12.98x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of 81.15%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 148.17%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $217.70 which suggests that it could grow by 0.47%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.228, which suggesting that the stock is 77.201% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 33.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.35x versus 17.75x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics, Inc. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of 19.97%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat TG Therapeutics, Inc.'s return on equity of 145.71%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 148.17%. On the other hand TG Therapeutics, Inc. has an analysts' consensus of $44.29 which suggests that it could grow by 40.1%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than TG Therapeutics, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than TG Therapeutics, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.228, which suggesting that the stock is 77.201% less volatile than S&P 500. In comparison TG Therapeutics, Inc. has a beta of 2.014, suggesting its more volatile than the S&P 500 by 101.386%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. TG Therapeutics, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are smaller than TG Therapeutics, Inc. quarterly revenues of $161.7M. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is lower than TG Therapeutics, Inc.'s net income of $390.9M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while TG Therapeutics, Inc.'s PE ratio is 11.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.35x versus 9.61x for TG Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.